BusinessCellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I TrialBy Nasdaq OMXMar 16, 2018, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessRural Providers Narrow Population Health Disparities Through ACO ParticipationBy Nasdaq OMXJul 18, 2017, 8:00 PM UTC
BusinessCellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXDec 9, 2016, 1:00 PM UTC
BusinessCascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support RegistrationBy Nasdaq OMXDec 7, 2016, 12:00 PM UTC
BusinessCascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast CancerBy Nasdaq OMXOct 10, 2016, 11:10 AM UTC
BusinessOncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 8, 2015, 9:05 PM UTC
